Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 7Breast Neoplasms 4Multiple Myeloma 2Stomach Neoplasms 1Sarcoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × 1-dodecylpyridoxal × Clear all
NCT04877275 2023-12-06

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
50 enrolled
Plasma cell

Multiple Myeloma

NCT00750815 2014-01-20

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
58 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡